Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT04033302
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Months - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CD7-specific CAR gene-engineered T cells — BIOLOGICAL
    Infusion of CD7-specific CAR-T cells

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.

Key Dates

First listed
Jul 26, 2019
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm
    Multiple CAR T cells to treat CD7-positive hematological malignancies

Primary Outcome Measure

Safety of infusion [ Time Frame: a year ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies